Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Colorectal Neoplasms 9Stomach Neoplasms 6Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Solid Tumor 3Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Transitional Cell 2Advanced Solid Tumors 2Advanced Solid Tumor 2Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Muscle Invasive Bladder Cancer 1

Interventions

toripalimab 2pembrolizumab 2tislelizumab 1spartalizumab 1sintilimab 1camrelizumab 1Taxes 1Cyclophosphamide 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Locally Advanced or Metastatic Solid Tumors × tislelizumab × Clear all
NCT05699811 2023-04-28

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Chinese PLA General Hospital

Phase 1/2 Recruiting
40 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡